Serranator 装置膝下动脉锯齿状成形术的前瞻性研究:PRELUDE BTK 研究
前瞻性、多中心、单臂可行性研究纳入 46 例跛行或慢性肢体威胁性缺血(RCC 3–5 级)需治疗踝关节以上膝下动脉的患者。装置成功率为 91.7%,30 天内免于主要不良肢体事件和围手术期死亡为 95.7%,术前狭窄 82% 降至 21.8%,仅 1 处病变(1.9%)因 D 级夹层需补救性支架。6 个月免于临床驱动的靶病变血运重建为 97.7%。
要点
- 装置成功率为 91.7%,30 天内免于主要不良肢体事件和围手术期死亡为 95.7%。
- 术前狭窄 82% 降至 21.8%,仅 1 处病变(1.9%)因 D 级夹层需补救性支架。
- 6 个月时 70% 患者 RCC 评分改善至少 1 级,42% 评分为 0,免于 CD-TLR 为 97.7%。
核心结论
- Serranator 治疗膝下病变显示优异的管腔获得,动脉损伤证据极少,6 个月 CD-TLR 低。
- IVUS 和 OCT 显示锯齿存在而无明显夹层,支持该装置提出的作用机制。
研究设计与样本
- 前瞻性、多中心、单臂可行性研究,纳入 46 例跛行或慢性肢体威胁性缺血(RCC 3–5 级)需治疗踝关节以上膝下动脉的患者。
- 共治疗 55 处病变,其中 53 处病变经核心实验室判定可分析并报告后续数据。
- 主要疗效终点为装置成功:成功插入、球囊充盈和回缩、移除装置且最终直径狭窄 <50%。
- 主要安全性终点为术后 30 天内主要不良肢体事件(MALE)和围手术期死亡(POD)的复合终点。
- 9 例患者亚组接受 OCT 或 IVUS 评估治疗病变中锯齿的存在,随访在 30 天和 6 个月进行。
主要发现
- 装置成功率为 91.7%,30 天内免于 MALE + POD 为 95.7%。
- 术前狭窄 82% 降至 21.8%,仅 1 处病变(1.9%)因 D 级夹层需补救性支架。
- 平均最大球囊充盈压力为 6 个大气压。
- 9 例患者经 OCT/IVUS 成像并由核心实验室审核,所有治疗病变(n=10)均存在锯齿。
- 6 个月时 70% 患者 RCC 评分改善至少 1 级,42% 评分为 0;6 个月免于 CD-TLR 为 97.7%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose was to evaluate the safety and efficacy of the Serranator percutaneous transluminal angioplasty serration balloon catheter in patients with infrapopliteal peripheral artery disease. MATERIALS AND METHODS: A prospective, multicenter, single-arm feasibility study in 46 patients with claudication or chronic limb-threatening ischemia, Rutherford Clinical Category (RCC) 3 to 5, that required treatment of the infrapopliteal arteries above the tibiotalar joint. The primary efficacy outcome was device success-successful insertion, balloon inflation and deflation, and removal of the device(s) with a final diameter stenosis of <50%. The primary safety endpoint was a composite of major adverse limb events (MALE) and perioperative death (POD) through 30 day postprocedure. Other outcomes were change in RCC and ankle-brachial index, wound healing, and clinically-driven target lesion revascularization (CD-TLR). A subset of 9 patients were further evaluated by optical coherence tomography (OCT) or intravascular ultrasound (IVUS) for the presence of serrations in treated lesions. Patient follow-up occurred at 30 days and 6 months. RESULTS: Forty-six patients received treatment with the Serranator device and 55 lesions were treated. Fifty-three lesions were deemed analyzable by the core lab with data and reported hereafter. Device success was 91.7% and freedom from MALE + POD through 30 days was 95.7%. Pretreatment stenosis of 82% was reduced to 21.8% and only 1 lesion (1.9%) required a bailout stent for a grade D dissection. The average maximum balloon inflation pressure was 6 atmospheres. Serrations were present in all treated lesions (n=10) in 9 patients imaged with OCT/IVUS as reviewed by the core laboratory. The RCC score improved by 1 or more level in 70% of patients at 6 months with 42% having a score of 0. The 6 month freedom from CD-TLR was 97.7%. CONCLUSION: Serranator treatment of infrapopliteal lesions showed excellent lumen gain with minimal evidence of arterial injury and low 6 month CD-TLR. Imaging by IVUS and OCT showed serrations without significant dissection, supporting the device's proposed mechanism of action.
引用
- Holden A, Lichtenberg M, Nowakowski P, et al. Prospective Study of Serration Angioplasty in the Infrapopliteal Arteries Using the Serranator Device: PRELUDE BTK Study. J Endovasc Ther. 2021. PMID: 34802313. doi:10.1177/15266028211059917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。